© 2002 by Heart
JournalScan
Cardiovascular highlights from non-cardiology journals
| The first 150 words of the full text of this article appear below. |
ISCHAEMIC HEART DISEASE
Treat a "normal" cholesterol if the patient is at vascular risk
In over 20 000 patients with proven coronary artery disease, other vascular disease or diabetes, simvastatin 40 mg was compared to placebo. Considering that 17% in the placebo arm were on a statin, and 85% in the treatment arm took the drug, the effect of treatment at five years was a significant reduction in all cause mortality (12.9% v 14.7%, p = 0.0003). This was due to a highly significant 18% (standard error 5) proportional reduction in the coronary death rate (5.7% v 6.9%, p = 0.0005). The rates of cerebrovascular accident, non-fatal myocardial infarction, and revascularisation were also reduced. Low density lipoprotein (LDL) was reduced by 1 mmol/l on average, starting from an average of 3.3 mmol/l. The benefits remain for patients with total cholesterol < 5 mmol/l and LDL < 3 mmol/l.
Heart Protection Study Collaborative Group
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
